The computerized cancer registry of Shaukat Khanum Memorial Cancer Hospital and Research Center (SKMCH&RC), Lahore, Pakistan, is a data system designed for the collection, management, and analysis of detailed data on patients registered at the facility. The hospital-based cancer registry has been functioning since the inauguration of the hospital in Lahore in December 1994. Every year, the Registry generates cancer statistics according to sex, age, demographic area, topography, morphology, stage, grade, etc. From December 1994 until December 2003, the International Classification of Diseases, Ninth Revision, Clinical Modification, was used to code the diseases. In January 2004, the Registry implemented the International Classification of Disease for Oncology, Third Edition (ICD-O-3) to code cancer cases. The Registry also implemented the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) in 2013, to do an in-depth coding of cancer and non-cancer cases.
|Patients reported include those registered at the centers affiliated with the Shaukat Khanum Memorial Trust and accessioned into the computerized cancer registry within the hospital information system in Lahore. The centers affiliated include two hospitals ‘Shaukat Khanum Memorial Cancer Hospital and Research Center’ in Lahore and Peshawar; the Karachi Diagnostic Center (KDC); and the Shaukat Khanum Diagnostic Center Liberty (SKDCL), Lahore. SKMCH&RC Lahore is the oldest center and has been functioning since December 29, 1994, SKMCH&RC Peshawar since December 29, 2015, the KDC since 2010, and SKDCL since August 1, 2019.|
During the last 26 years, a total of 111,783 neoplasms were registered at SKMCH&RC, KDC, and SKDCL; 6,823 were benign and 104,960 were malignant. The distributions seen among males and females were 47.6% and 52.4%, respectively. About 90.4% of the tumors were found in adults, whereas 9.6% were diagnosed in children. The top three malignancies in all age-groups, both sexes combined were breast cancer, colon, rectum, anal canal and anus cancers, and leukemia. The top three malignancies among adult females were: cancers of the breast, ovary & uterine adnexa, and lip & oral cavity, while, in adult males, colon, rectum, anal canal and anus, prostate, and lip & oral cavity cancers.
In adults, regardless of sex, malignant neoplasm of the breast, colon, rectum, anal canal and anus, and lip & oral cavity, were established as the leading malignancies and in children, acute lymphoblastic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma were recorded as the commonest malignancies.
In the year 2020, a total of 7,267 neoplasms were added to the Registry database, of which 559 were benign and 6,708 malignant. Of 6,708 malignant cases, 6,563 (97.8%) were analytical cases, whereas 145 (2.2%) were non-analytical cases. Class of Case 0 to 2 are considered analytical and 3 to 9 non-analytical cases, according to the Facility Oncology Revised Data Standards (FORDS) Revised for 2004. In cancer registration, analytical cases are included in treatment and survival analysis, while non-analytical cases are usually not included in routine treatment or survival statistics.
The top three malignancies in all age-groups, both sexes combined were breast, colon, rectum, anal canal and anus, and non-Hodgkin lymphoma. In adult males, colon, rectum, anal canal and anus, prostate, and non-Hodgkin lymphoma were the top malignancies, whereas, in adult females, breast, ovary, and colon, rectum, anal canal and anus were the leading malignancies. In children, Hodgkin lymphoma, acute lymphoblastic leukemia, and osteosarcoma were the commonest malignancies.
The Registry uses the American Joint Committee on Cancer (AJCC 8th edition) staging manual for staging all available cancer sites. TNM categorizes cancers in stages 0, 1, 2, 3, 4, and also as unstageable and not applicable. Among 6,563 analytical cases, 0.8% cases were staged into Stage 0, 12.9% in Stage I, 27.2% in Stage II, 25.4% in Stage III, and 18.2% in Stage IV. In 10.2% of the patients, no AJCC stage was defined and 5.3% of the cases were unstageable.
According to the SEER summary staging manual-2000 codes and coding instructions, 0.5% cases were in-situ, 22.1% localized, 44.5% regional, and 20.3% distant. In 12.6% of the cases, the summary stage was unknown.
|By histological grading/differentiation/immunophenotype, 6.8% presented in Grade I, 31.8% in Grade II, 25.9% in Grade III, 1.8% in Grade IV, 0.4% T-cell, 5.3% B-cell, and grade/differentiation/immunophenotype not determined, not stated, or not applicable in 28.0%.||
Click here to view reports
The details of these reports can be viewed by using the following links: Collective Cancer Registry Report - Dec. 1994 to Dec. 2020 (PDF file) Annual Cancer Registry Report - 2020 (PDF file) CRCDM - Confidentiality - August, 2020 (PDF file) Archived Cancer Registry Reports 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |… more details »